News
  Date Title View
Mar 27, 2014
- Strong cash position bolstered with additional $75 million from IPO -- Lead drug candidate, FX006, planned to enter into confirmatory Phase 2b trial in osteoarthritis of the knee - - Second clinical candidate, FX007, expected to enter Phase 2 proof-of-concept trial later in 2014 - BURLINGTON, Mass., March 27, 2014 (GLOBE NEWSWIRE) -- Flex...
Mar 20, 2014
BURLINGTON, Mass., March 20, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its year-end 2013 financial results on Thursday, March 27, 2014, at 4 p.m. ET. The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) 9...
Feb 26, 2014
BURLINGTON, Mass., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 34th Annual Cowen Health Care Conference. Dr. Clayman's presentation is scheduled for March 3, 2014, at 4:50 p.m. Eastern Time. The Conference will take place Ma...
Feb 18, 2014
BURLINGTON, Mass., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the closing of its initial public offering of 5,750,000 shares of its common stock at an initial public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 750,000 ad...
Feb 11, 2014
BURLINGTON, Mass., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a price to the public of $13.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "FLXN" on February 12...
Jan 8, 2014
BURLINGTON, MASS., JANUARY 8, 2014 - Flexion Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering of shares of its common stock.  All of the shares to be sold in the offering will be offered by Flexion. T...
Oct 30, 2013
BURLINGTON, MASS., OCTOBER 30, 2013 -  Flexion Therapeutics, Inc. announced today that new data from a Phase 2b dose-ranging clinical trial of the company's lead compound, FX006, were presented at the  2013 American College of Rheumatolog...
Oct 2, 2013
BURLINGTON, MASS., OCTOBER 2, 2013 - Flexion Therapeutics, Inc. announced today that new data from a Phase 2b dose-ranging trial of the company's lead compound, FX006, in osteoarthritis (OA) has been accepted for an oral presentation at the 2013 Annual Scientific Meeting of the American Co...
Jun 26, 2013
BURLINGTON, Mass., June 26, 2013 - Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular (IA), sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release s...
May 20, 2013
WOBURN, Mass., May 20, 2013 -  Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies. P...
FirstPrevious ...
12
NextLast
= add release to Briefcase